Division III · Therapeutics

Delivering the Future of
RNA Medicine Today.

Pioneering next-generation mRNA therapeutics using proprietary SNIM® RNA and SNaP LNP® platforms. Our multi-route delivery system enables precise therapies.

Collaborate With Us Explore AI Platform

Advancing RNA
Delivery.

Historically, mRNA therapies have been limited by inherent instability. Unlocking their full potential requires stabilized molecules and advanced delivery.

SNIM® RNA Platform

Our Stabilized Non-Immunogenic mRNA technology overcomes instability through chemical modifications. It can be administered repeatedly to drive sustained protein production without triggering unwanted immunity.

SNaP LNP® Platform

Stabilized Lipidoid Nanoparticles capable of transporting mRNA via inhalation directly to the respiratory tract, allowing for highly targeted and stable dry powder forms independent of cold chains.

Therapeutic Sequencing

Programmable
Intervention.

PHASE .01

Genomic Sequencing

Full-profile diagnostics to chart individual RNA expression maps and uncover specific pathogenic mutations.

PHASE .02

mRNA Design

Computational generation of the precise SNIM® RNA sequence required to trigger therapeutic protein production.

PHASE .03

Targeted Delivery

Encapsulation within SNaP LNP® matrices for aerosolized or intravenous transport directly to the site of action.

Four pillars of
personalized care.

Genomic Profiling

Patient-specific genomic data informs compound selection and dosage optimization.

mRNA Therapeutics

Programmable mRNA-based therapies targeting inherited metabolic and immune disorders.

Biomarker-Guided Dosing

Real-time biomarker monitoring enables adaptive treatment protocols for optimal outcomes.

Patient-Reported Outcomes

Digital endpoints and PRO tools capture real-world efficacy beyond clinical settings.

Clinical Pipeline &
Target Areas

Addressing complex diseases with unmet medical needs using programmable multi-cargo delivery.

Asthma & COPD

Innate Immune Defense

Candidate: ETH47

First-in-class therapy correcting low interferon lambda levels to prevent virus-driven asthma attacks. Addresses a critical need for 4.4M uncontrolled asthmatics.

Mucosal Vaccines

Preventative

Candidate: Spray-Dried RNA

Stable at room temperature, our SNaP LNP® technology is capable of generating localized immune responses directly at the entry site of respiratory pathogens.

Protein Replacement

Rare Genetic Disorders

Candidate: PCD Reconstitution

Delivering corrected mRNA designed to produce ciliary proteins directly in the respiratory tract to counter rare diseases like Primary Ciliary Dyskinesia.

Strategic Resilience

Scalable Biodefense & Manufacturing.

Our in-house developed technologies, CDMO partnerships, and aerosolized delivery methods bypass deep-freeze cold chains. We aim to reduce the burden of virus-induced hospitalizations rapidly.

By establishing a highly stable, HPLC-free manufacturing framework, Solenyx operates as a responsive infrastructure for emerging pathogens and immediate strategic biodefense.

Shape the future of
personalized care.

We welcome academic, clinical, and industry partners to co-develop next-generation RNA therapies.

Partner Inquiry AI Discovery Platform

Delivering the Future of RNA Medicine Today.

Advancing RNA Delivery.